Paper30615985
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR and 8 others. Diabetes Metab, 2019. Cited by 229 papers, by iCite.
Cite this record
ConductScience Library. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Papers, record 30615985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30615985
- Disease
- type 2 diabetes mellitus613 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Glucagon-Like Peptides | Major topic |
| Hypoglycemic Agents | Major topic |
| Incretins | Major topic |
| Glucagon-Like Peptide-1 Receptor Agonists | Major topic |
| Humans | |
| Injections, Subcutaneous | |
| Treatment Outcome | |
| Semaglutide |
Source PubMed
Trials7
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01720446 | Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | Results | ClinicalTrials.gov | |
| NCT01885208 | Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Results | ClinicalTrials.gov | |
| NCT01930188 | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Results | ClinicalTrials.gov | |
| NCT02054897 | Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes | Results | ClinicalTrials.gov | |
| NCT02128932 | Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes | Results | ClinicalTrials.gov | |
| NCT02305381 | Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes | Results | ClinicalTrials.gov | |
| NCT02648204 | Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | Results | ClinicalTrials.gov |
Cited by139
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 229 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42890485 | GLP-1 RA Eligibility in Reproductive-Age U.S. Women. | Diabetes Obes Cardiometab CARE | 2026 | https://conductscience.org/library/papers/42890485 | PubMed |
| 42747132 | Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review. | Endocrinol Diabetes Metab | 2026 | https://conductscience.org/library/papers/42747132 | PubMed |
| 42651699 | For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better? | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42651699 | PubMed |
| 42622874 | Investigating the impact of Glucagon-like peptide-1 therapy on total shoulder arthroplasty outcomes. | Int Orthop | 2026 | https://conductscience.org/library/papers/42622874 | PubMed |
| 42620396 | Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok. | Front Public Health | 2026 | https://conductscience.org/library/papers/42620396 | PubMed |
| 42432542 | Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report. | BMC Ophthalmol | 2026 | https://conductscience.org/library/papers/42432542 | PubMed |
| 42403263 | Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42403263 | PubMed |
| 42305970 | A systematic review of semaglutide-associated kidney injury case reports. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42305970 | PubMed |
| 42297449 | The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients. | Schizophr Bull | 2026 | https://conductscience.org/library/papers/42297449 | PubMed |
| 42278227 | Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278227 | PubMed |
| 42253408 | Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus. | Metabol Open | 2026 | https://conductscience.org/library/papers/42253408 | PubMed |
| 42232304 | Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism. | Front Clin Diabetes Healthc | 2026 | https://conductscience.org/library/papers/42232304 | PubMed |
| 42219226 | Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42219226 | PubMed |
| 42198407 | Oral GLP-1-Based Therapeutics in the Obesity-Metabolic Syndrome-Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198407 | PubMed |
| 42185271 | Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us. | Nat Commun | 2026 | https://conductscience.org/library/papers/42185271 | PubMed |
| 42144979 | GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review. | Alcohol Clin Exp Res (Hoboken) | 2026 | https://conductscience.org/library/papers/42144979 | PubMed |
| 42099530 | Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective. | Clinicoecon Outcomes Res | 2026 | https://conductscience.org/library/papers/42099530 | PubMed |
| 42099097 | Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts. | JMIR Infodemiology | 2026 | https://conductscience.org/library/papers/42099097 | PubMed |
| 42072382 | Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review. | Biomedicines | 2026 | https://conductscience.org/library/papers/42072382 | PubMed |
| 41984016 | Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus. | J Am Coll Cardiol | 2026 | https://conductscience.org/library/papers/41984016 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Drugs5
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| INSULIN GLARGINE | CHEMBL1201497 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1201497 | ChEMBL |
| SITAGLIPTIN | CHEMBL1422 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1422 | ChEMBL |
| DULAGLUTIDE | CHEMBL2108027 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL2108027 | ChEMBL |
| SEMAGLUTIDE | CHEMBL2108724 | Results | 7 | https://conductscience.org/library/drugs/CHEMBL2108724 | ChEMBL |
| EXENATIDE | CHEMBL414357 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL414357 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30615985
GET https://conductscience.org/api/papers/v1/30615985/cited_by?page=2